Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
SYMBICORT AEROSPHERE is a metered-dose aerosol combination inhaler containing budesonide (inhaled corticosteroid) and formoterol fumarate (long-acting beta-2 agonist) approved in April 2023. It is indicated for maintenance and relief treatment of asthma and chronic obstructive pulmonary disease (COPD) in patients aged 6 years and older. The formulation uses AstraZeneca's proprietary Aerosphere technology to deliver improved lung deposition and consistent dosing.
Recently approved product in peak commercial expansion phase; expect growing team investment in market development and access programs.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
LOE in ~4 years — strategic planning for patent cliff underway
Worked on SYMBICORT AEROSPHERE at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
SYMBICORT AEROSPHERE is a peak-stage respiratory asset in a high-competition market offering strong commercial visibility and career momentum through product launch maturation and market expansion. Working on this product provides exposure to established therapeutic area dynamics, competitive market strategy, and multi-stakeholder engagement (payers, physicians, patients) across asthma/COPD populations.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo